Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesUscom Ltd

Uscom Ltd

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.012 AUD 0.00(0%)
Last update at 2026-11-10T23:00:00Z
Market Cap
3.12M

Momentum Score

…

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices in Australia, Asia, the Americas, and Europe. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures blood flow, stroke volume, and cardiac output; and BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm. The company also provides the SpiroSonic Ultrasonic spirometer, a pulmonary function testing device that uses multi-path ultrasound; SpiroSonic FLO and SpiroSonic AIR, a digital multi-path ultrasonic spirometer for pulmonary function diagnostic and monitoring COPD and asthma; and SpiroSonic SMART for use by general practitioners and patients for screening COPD and asthma. It serves hospitals and medical care locations through its distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.01
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Uscom Ltd is an Australian medical technology company that develops and supplies non-invasive haemodynamic monitoring devices for clinical settings. Long-term growth may be supported by demographic trends increasing demand for cardiovascular diagnostics, wider clinical adoption of non-invasive monitoring, and expanded regulatory approvals and market access. Investors may find the company attractive because it appears positioned in a specialized niche with proprietary technology and potential for revenue expansion if adoption continues.

Principal risks include limited scale and cashflow, execution and financing risk, regulatory and reimbursement uncertainty, and competitive pressures that could constrain commercial traction.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
2.41M
Revenue Per Share
0.01
Gross Profit TTM
2.06M
Debt / Equity
-59.22
ROE
-110.01%
Net Debt
1.30M
ROCE
-700.02%
Diluted EPS TTM
-0.02

Insight News

View All

Insight Announcement

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -3.25M -2.03M -2.56M -1.94M -0.88M
Net income -3.30M -2.07M -2.59M -1.97M -0.92M
Selling general administrative 4.83M 3.69M 3.44M 4.85M 2.74M
Selling and marketing expenses 1.09M 1.07M 0.95M 0.66M 0.63M
Gross profit 2.23M 3.12M 2.25M 2.91M 3.37M
Reconciled depreciation - 0.39M 0.38M 0.42M 0.40M
Ebit -3.20M -1.90M -2.45M -2.36M -0.79M
Ebitda -3.06M -1.51M -2.07M -1.94M -0.39M
Depreciation and amortization 0.14M 0.39M 0.38M 0.42M 0.40M
Operating income -3.73M -2.38M -2.45M -2.36M -0.79M
Other operating expenses 6.31M 6.13M 5.58M 5.19M 5.29M
Interest expense 0.13M 0.13M 0.10M 0.08M 0.10M
Tax provision 0.05M 0.05M 0.03M 0.03M 0.04M
Interest income 0.09M 0.05M 0.13M 0.04M 0.03M
Net interest income - -0.09M -0.05M -0.06M -0.06M
Income tax expense 0.05M 0.05M 0.03M 0.03M 0.04M
Total revenue 2.58M 3.73M 2.66M 3.25M 3.86M
Total operating expenses 5.96M 5.52M 5.16M 4.85M 4.81M
Cost of revenue 0.35M 0.61M 0.42M 0.34M 0.49M
Total other income expense net 0.48M 0.35M 0.41M 0.42M -0.10M
Net income from continuing ops - -2.07M -2.59M -1.97M -0.92M
Net income applicable to common shares -3.30M -2.07M -2.59M -1.97M -0.92M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 3.25M 5.13M 5.18M 7.99M 5.33M
Intangible assets 0.01M - 0.50M 0.48M 0.47M
Other current assets 0.66M - 0.00M 0.40M 0.44M
Total liab 3.29M 2.07M 2.14M 2.06M 2.26M
Total stockholder equity -0.04M 3.06M 3.04M 5.94M 3.08M
Other current liab 0.69M 0.68M -0.00M 0.20M 0.62M
Common stock 40.44M 40.42M 38.51M 39.14M 34.67M
Capital stock - - 38.51M 39.14M 34.67M
Retained earnings -44.88M -41.58M -39.50M -36.91M -34.94M
Other liab - - 0.09M 0.07M 0.07M
Other assets - 0.00M 0.08M 0.08M 0.08M
Cash 0.97M 1.05M 2.18M 4.70M 1.71M
Cash and equivalents - - 0.30M 3.02M 0.02M
Total current liabilities 2.79M 1.28M 1.21M 0.90M 0.95M
Current deferred revenue - - 0.67M - -
Net debt 1.30M -0.06M -1.09M -3.39M -0.28M
Short term debt 1.90M 0.30M 0.26M 0.22M 0.19M
Short long term debt total 2.26M 0.99M 1.09M 1.31M 1.43M
Other stockholder equity - 0.00M 0.10M 3.71M 3.35M
Property plant equipment - - 0.86M 1.12M 1.33M
Total current assets 2.65M 3.87M 3.74M 6.31M 3.45M
Net tangible assets - - 2.53M 5.45M 2.61M
Short term investments - 1.47M - - -
Net receivables 0.22M 0.72M 0.37M 0.34M 0.40M
Inventory 0.80M 0.62M 0.75M 0.87M 0.89M
Accounts payable 0.20M 0.30M 0.28M 0.48M 0.14M
Accumulated other comprehensive income 4.41M 4.22M 4.04M 3.71M 3.35M
Non currrent assets other - 0.42M 0.08M 0.08M 0.08M
Non current assets total 0.60M 1.27M 1.44M 1.68M 1.88M
Capital lease obligations - - 1.09M 1.31M 1.43M
Long term debt total - - 0.83M 1.09M 1.24M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - -0.06M -0.15M -0.12M -0.03M
Change to liabilities - - 0.47M -0.02M 0.03M
Total cashflows from investing activities -0.07M -0.06M -0.15M -0.12M -0.03M
Net borrowings - - -0.31M -0.26M -0.27M
Total cash from financing activities 1.21M 1.57M -0.95M 4.05M -0.28M
Change to operating activities - - -0.11M 0.06M -0.02M
Net income -3.30M -2.07M -2.59M -1.97M -0.92M
Change in cash -1.55M 0.34M -2.53M 2.99M -0.21M
Begin period cash flow 2.52M 2.18M 4.70M 1.71M 1.92M
End period cash flow 0.97M 2.52M 2.18M 4.70M 1.71M
Total cash from operating activities -2.71M -1.16M -1.42M -1.56M 0.05M
Issuance of capital stock - 2.00M - 4.36M -
Depreciation 0.39M 0.39M 0.36M 0.42M 0.40M
Other cashflows from investing activities -0.05M -0.05M - - -
Change to inventory -0.18M 0.13M 0.12M 0.02M -0.07M
Change to account receivables 0.02M 0.06M -0.03M 0.00M 0.05M
Sale purchase of stock 0.00M -0.09M -0.64M -0.05M -0.01M
Other cashflows from financing activities 1.57M -1.54M -0.31M -0.26M -0.27M
Change to netincome - - 0.34M 0.53M 0.58M
Capital expenditures 0.01M 0.06M 0.15M 0.12M 0.03M
Change in working capital -0.19M 0.38M 0.44M 0.71M 0.73M
Stock based compensation 0.17M 0.23M - - -
Other non cash items 0.22M -0.09M - 1.56M 0.53M
Free cash flow -2.72M -1.22M -1.58M -1.67M 0.02M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
UCM
Uscom Ltd		 -
-%		 0.01 - - 1.29 2.16 1.71 -2.72
COH
Cochlear Ltd		 2.26
1.50%		 152.98 68.64 27.40 4.30 5.34 3.97 28.09
IMR
Imricor Medical Systems Inc		 0.06
4.72%		 1.33 - - 36401.21 17.45 4019.33 -2.60
AVR
Anteris Technologies Global Corp		 0.50
5.88%		 9.00 - - 356.02 2.19 130.34 -5.20
AVH
Avita Medical Inc		 -0.11
2.13%		 5.06 - 9.97 9.59 7.17 6.76 15.37

Profile*

Uscom Ltd

Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices in Australia, Asia, the Americas, and Europe. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures blood flow, stroke volume, and cardiac output; and BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm. The company also provides the SpiroSonic Ultrasonic spirometer, a pulmonary function testing device that uses multi-path ultrasound; SpiroSonic FLO and SpiroSonic AIR, a digital multi-path ultrasonic spirometer for pulmonary function diagnostic and monitoring COPD and asthma; and SpiroSonic SMART for use by general practitioners and patients for screening COPD and asthma. It serves hospitals and medical care locations through its distribution partners. The company was formerly known as Uscom Pty Limited and changed its name to Uscom Limited in October 2003. The company was incorporated in 1999 and is headquartered in Sydney, Australia.

66 Clarence Street, Sydney, NSW, Australia, 2000

61 2 9247 4144

https://www.uscom.com.au

Name Title Year Born
Dr. Robert Allan Phillips DMU, Ph.D.(Med), AMS, MPhil (Med), FASE, FIR Founder, Exec. Chairman, CEO & Chief Scientist 1953
Mr. Brett Thomas Crowley B.Com., BCom, C.A., CA, DipLaw Company Sec. & Non-Exec. Director 1957
Mr. Nicholas Schicht Gen. Mang. 1966
Dr. Robert Allan Phillips AMS, DMU, FASE, FIR, MPhil (Med), Ph.D.(Med) Founder, Executive Chairman, CEO & Chief Scientist 1953
Mr. Brett Thomas Crowley B.Com., BCom, C.A., CA, DipLaw Company Secretary & Non-Executive Director 1957
Mr. Nicholas Schicht General Manager 1966
Dr. Robert Allan Phillips AMS, DMU, FASE, FIR, MPhil (Med), Ph.D.(Med) Founder, Executive Chairman, CEO & Chief Scientist 1953
Mr. Brett Thomas Crowley B.Com., BCom, C.A., CA, DipLaw Company Secretary & Non-Executive Director 1957
Mr. Nicholas Schicht General Manager 1966
Dr. Robert Allan Phillips AMS, DMU, FASE, FIR, MPhil (Med), Ph.D.(Med) Founder, Executive Chairman, CEO & Chief Scientist 1953

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…